There’s a form of heart failure that may be more common than thought. And there’s no treatment for it.
But an existing drug just passed a critical step and may soon be approved to treat this overlooked condition.
On average, people live three to five years after getting a diagnosis of transthyretin amyloid cardiomyopathy, or ATTR-CM.
To read the entire article, please click here.